| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/04/2006 | EP0923606B1 Antigenic fusionprotein carrying galalpha1,3gal epitopes |
| 01/04/2006 | CN1717488A Recombinant poxvirus comprising at least two cowpox ATI promoters |
| 01/04/2006 | CN1717417A Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases |
| 01/04/2006 | CN1717251A Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 01/04/2006 | CN1717250A Anti-cancer and anti-infectious disease compositions and methods for using same |
| 01/04/2006 | CN1715410A Clone of duckwheat allergic storage protein gene and its use |
| 01/04/2006 | CN1714865A Natural molecular submit vaccine for anti-Japanese snail fever |
| 01/04/2006 | CN1234845C M. smegmatics vaccine |
| 01/04/2006 | CN1234413C Synergistic composition and its use |
| 01/04/2006 | CN1234412C Method for large-scale continuous production of virus vaccine |
| 01/03/2006 | US6982326 Allergenic proteins and peptides from Japanese cedar pollen |
| 01/03/2006 | US6982320 Cytokine receptor common gamma chain like |
| 01/03/2006 | US6982314 Lawsonia intracellularis proteins, and related methods and materials |
| 01/03/2006 | US6982160 Immunogenic compositions that include SIRS virus |
| 01/03/2006 | US6982156 comprises antibodies against Smallpox Inhibitor of Complement Enzyme (SPICE) or Vaccinia Virus Complement Control Protein (VCP); dna vaccines |
| 01/03/2006 | US6982154 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease |
| 01/03/2006 | US6982089 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 01/03/2006 | US6982088 Vaccine composition and stabilization method using high molecular weight PVP |
| 01/03/2006 | US6982087 Attenuating mutations and methods of making them, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue |
| 01/03/2006 | US6982086 Human immunodeficiency virus immunogenic composition |
| 01/03/2006 | US6982085 Induce antibody response; drugs, medical diagnosis |
| 01/03/2006 | US6982084 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 01/03/2006 | CA2162586C Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| 01/01/2006 | CA2502425A1 Allergen from house-dust mites |
| 12/30/2005 | CA2511084A1 Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications |
| 12/29/2005 | WO2005124346A1 4-1bb receptors are expressed on regulatory t-cells |
| 12/29/2005 | WO2005123908A2 Novel cancer cell lines and uses thereof |
| 12/29/2005 | WO2005123777A2 Method of treating granuloma annulare or sarcoid |
| 12/29/2005 | WO2005123775A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
| 12/29/2005 | WO2005123773A1 Method for site-directed immunisation |
| 12/29/2005 | WO2005123764A1 Preparation of protective antigen from bacillus anthracis |
| 12/29/2005 | WO2005123129A2 Methods of redistributing apical target antigens to detect and treat cellular proliferative disease |
| 12/29/2005 | WO2005123128A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 12/29/2005 | WO2005123127A2 Methods for treating cancer using prss15 as a target |
| 12/29/2005 | WO2005123126A2 Antibodies against human interleukin-13 and uses therefor |
| 12/29/2005 | WO2005123125A1 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
| 12/29/2005 | WO2005123124A1 Q fever vaccine preparation and method of producing the vaccine |
| 12/29/2005 | WO2005123123A2 Therapeutic reprogramming, hybrid stem cells and maturation |
| 12/29/2005 | WO2005123122A1 Peptide vaccine for cancer therapy |
| 12/29/2005 | WO2005123121A2 Use of dna molecule as vaccine adjuvant |
| 12/29/2005 | WO2005123120A1 Sustained release vaccine composition |
| 12/29/2005 | WO2005123112A2 Method of enhancing the immune response to a vaccine |
| 12/29/2005 | WO2005123104A2 Use of vegf inhibitors for the treatment of human cancer |
| 12/29/2005 | WO2005123100A1 Lactic bacteria and their use in the prevention of diarrhea |
| 12/29/2005 | WO2005122739A2 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
| 12/29/2005 | WO2005122718A2 Kennel cough vaccine |
| 12/29/2005 | WO2005116077A3 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
| 12/29/2005 | WO2005107793A3 Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| 12/29/2005 | WO2005107381A3 Use of flagellin as an adjuvant for vaccine |
| 12/29/2005 | WO2005106476A3 Method for diagnosing infectious diseases |
| 12/29/2005 | WO2005094364A3 Iga antibody protein as a cytotoxic drug |
| 12/29/2005 | WO2005084387A3 Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer |
| 12/29/2005 | WO2005079398A3 Drug conjugates |
| 12/29/2005 | WO2005077130A3 A method for the removal of aggregate proteins from recombinant samples using ion exchange chromatography |
| 12/29/2005 | WO2005065121A3 Methods and compositions for the production of monoclonal antibodies |
| 12/29/2005 | WO2005063802A3 Haemophilus influenzae type iv pili |
| 12/29/2005 | WO2005062893A3 Anti-cd52 antibody treatment for diabetes |
| 12/29/2005 | WO2005061542A3 Detection of cd20 in transplant rejection |
| 12/29/2005 | WO2005048943A3 Compositions and methods for synergistic induction of antitumor immunity |
| 12/29/2005 | WO2005043119A3 Methods and compositions for the identification of anti-poxvirus agents |
| 12/29/2005 | WO2005042698A3 T cell epitopes useful in a hepatitis c virus vaccine and as diagnostic tools and methods for identifying same |
| 12/29/2005 | WO2005040353A3 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv |
| 12/29/2005 | WO2005040352A3 Immunogenic composition and method of developing a vaccine based on factor h binding sites |
| 12/29/2005 | WO2005037190A3 Multiplex vaccines |
| 12/29/2005 | WO2005035733A3 Modified whole cell, cell extract and omv-based vaccines |
| 12/29/2005 | WO2005024038A3 Process for producing a capsular polysaccharide for use in conjugate vaccines |
| 12/29/2005 | WO2005021034A3 Safe mutant viral vaccines |
| 12/29/2005 | WO2005020889A3 Functional influenza virus-like particles (vlps) |
| 12/29/2005 | WO2005019411A3 Ancestral viruses and vaccines |
| 12/29/2005 | WO2005016115A3 Biosensors utilizing dendrimer-immobilized ligands and their use thereof |
| 12/29/2005 | WO2005013918A3 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 12/29/2005 | WO2004111608A8 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| 12/29/2005 | WO2004103269A3 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia |
| 12/29/2005 | WO2004101745A3 NOVEL REGULATORY MECHANISMS OF NF-kappaB |
| 12/29/2005 | WO2004094599A3 Disease prevention and vaccination following thymic reactivation |
| 12/29/2005 | WO2004074437A3 Compositions and methods for cancer immunotherapy |
| 12/29/2005 | WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 12/29/2005 | WO2004058191A3 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| 12/29/2005 | WO2004015073A3 MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 12/29/2005 | WO2004004661A3 Boroproline compound combination therapy |
| 12/29/2005 | WO2003072799A3 Brother of the regulator of imprinted sites (boris) |
| 12/29/2005 | WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use |
| 12/29/2005 | WO2002033113A3 Protein-protein interactions in neurodegenerative diseases |
| 12/29/2005 | US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 12/29/2005 | US20050289658 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 12/29/2005 | US20050288491 Super-humanized antibodies against respiratory syncytial virus |
| 12/29/2005 | US20050288487 Human mast cell-expressed membrane proteins |
| 12/29/2005 | US20050288299 Preferably p38-alpha; azaindoles, azabenzofurans, or azabenzothiophenes are coupled through a piperidine or piperazine type linker to another cyclic moiety; antiarthritic, anticarcinogenic, antiinflammatory agents; analgesics |
| 12/29/2005 | US20050288255 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| 12/29/2005 | US20050288218 Methods for treating and preventing sepsis using modified C1 inhibitor or fragments thereof |
| 12/29/2005 | US20050288214 Nucleotide sequence encoding PTD and CEA fusion protein, Tat-CEA fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein |
| 12/29/2005 | US20050287672 Avipox recombinants expressing foot and mouth disease virus genes |
| 12/29/2005 | US20050287647 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| 12/29/2005 | US20050287642 Efficient protein expression system |
| 12/29/2005 | US20050287631 Compositions and methods related to a dimeric MHC class I and II-Like molecule (dsMHCI and dsMHCII) |
| 12/29/2005 | US20050287628 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 12/29/2005 | US20050287609 Methods and compositions for detection of equine tapeworm infections |
| 12/29/2005 | US20050287554 Regions of papilloma virus E1 helicase involved in E1 oligomerization |
| 12/29/2005 | US20050287545 Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
| 12/29/2005 | US20050287540 Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences |